

Special Issue

Potential Therapeutic Molecules for SARS-CoV-2 Three Years since the Outbreak of COVID-19

Message from the Guest Editor

Dear Colleagues: The recent outbreak of a novel coronavirus and its variants responsible for the coronavirus pandemic disease 2019 (COVID-19), which has caused infections with a high mortality rate around the world. Our understanding of COVID-19, including its detection, prevention (vaccination), and the various approaches to its treatment, have been increased daily for last three years. As a result, several COVID-19 vaccines have been approved for general or emergency use; however, still no specific antiviral drugs are available for the treatment of SARS-CoV-2. This warrants the search for new effective antiviral therapeutics against coronaviral infections. The present Special Issue of *Molecules*, titled 'Advances in Understanding of SARS-CoV-2 Three Years Since the Outbreak of COVID-19', aims to compile the latest knowledge on SARS-CoV-2 needed for the potential treatment of COVID-19.

Guest Editor

Dr. Mohammad Ajmal Ali

Department of Botany and Microbiology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia

Deadline for manuscript submissions

closed (31 May 2023)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/123039

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).